Have any questions? 706-721-6582 or cts@augusta.edu
- SGNTV-002 - Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen
Clinical Trial
SGNTV-002 - Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen
This study is being done to find out if tisotumab vedotin treats ovarian cancer. The goal is to see if patients with a certain type of ovarian cancer respond to the drug. Also, how long it takes for patients to respond to tisotumab vedotin and how long the response lasts. The study also wants to learn more about any side effects patients have when they get tisotumab vedotin.
Eligibility Criteria
- Patients must have a histologic documentation of epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. Patients must have received treatment with a bevacizumab-containing regimen for ovarian cancer. Patients must not have primary platinum-refractory disease, defined as disease progression within 2 months of completion of first line platinum-based therapy.
RESEARCH. INNOVATION. DISCOVERY.